3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
7
NIH
2
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
32
CNS
21
Lymphoid
8
Dermatologic
7
Genitourinary
6
Gastrointestinal
6
Endocrine
3
Thoracic
2
Other solid neoplasm
2
Head & Neck
2
Plasma cell
1
Other hematologic neoplasm
1
NET
1
Gynecologic
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
879
Leukemia, Lymphocytic, Chronic, B-Cell
560
Leukemia
426
Hematologic Neoplasms
332
Precursor Cell Lymphoblastic Leukemia-Lymphoma
331
Myelodysplastic Syndromes
302
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
244
Lymphoma, Non-Hodgkin
224
Recurrence
222
Lymphoma
196
Neoplasms
195
Multiple Myeloma
129
Lymphoma, Mantle-Cell
119
Lymphoma, Large B-Cell, Diffuse
114
Lymphoma, Follicular
114
Leukemia, Myelomonocytic, Chronic
89
Lymphoma, B-Cell
88
Lymphoma, B-Cell, Marginal Zone
85
Leukemia, B-Cell
79
Burkitt Lymphoma
64
Leukemia, Myeloid, Chronic-Phase
57
Waldenstrom Macroglobulinemia
56
Leukemia, Myeloid
53
Hodgkin Disease
47
Hematologic Diseases
47
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
45
Myeloproliferative Disorders
40
Primary Myelofibrosis
39
Bronchiolitis Obliterans Syndrome
35
Anemia, Refractory, with Excess of Blasts
32
Interventions
bempegaldesleukin
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Rhabdomyosarcoma
×
Other hematologic neoplasm
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts